Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 306

Sort by

Sort Order Select

Journal Articles

Comparison of progression risk of monoclonal gammopathy of undetermined significance by method of detection

Alissa Visram, Dirk Larson, Aaron D Norman, Angela Dispenzieri, David L Murray, Robert A Kyle, S. Vincent Rajkumar, Susan L. Slager, Shaji K Kumar, Celine M. Vachon

Blood blood.2024025415.

https://doi.org/10.1182/blood.2024025415

Published: 2024

Includes: Supplemental data

Journal Articles

Dexamethasone dose intensity does not impact outcomes in newly diagnosed multiple myeloma: a secondary SWOG analysis

Rahul Banerjee, Rachael Sexton, Andrew J. Cowan, Aaron S. Rosenberg, Sikander Ailawadhi, S. Vincent Rajkumar, Shaji K Kumar, Angela Dispenzieri, Sagar Lonial, Brian G.M. Durie, Paul G. Richardson, Saad Z Usmani, Antje Hoering, Robert Z Orlowski

Blood blood.2024025939.

https://doi.org/10.1182/blood.2024025939

Published: 2024

Includes: Supplemental data

Journal Articles

Prognostic impact of cytogenetic abnormalities by FISH in AL amyloidosis with daratumumab-based frontline therapy

Rajshekhar Chakraborty, Saurabh Zanwar, Ute Hegenbart, Divaya Bhutani, Morie A Gertz, Angela Dispenzieri, Shaji K Kumar, Anita D'Souza, Anannya Patwari, Andrew J Cowan, GuiZhen Chen, Paolo Milani, Giovanni Palladini, Vaishali Sanchorawala, Geethika Bodanapu, Stefan Schönland, Suzanne Lentzsch, Eli Muchtar

Blood blood.2024025899.

https://doi.org/10.1182/blood.2024025899

Published: 2024

Includes: Supplemental data

Journal Articles

Impact of cytogenetic abnormalities on the risk of disease progression in solitary bone plasmacytomas

Blood (2023) 142 (22): 1871–1878.

https://doi.org/10.1182/blood.2023021187

Published: 2023

Includes: Supplemental data

Journal Articles

Results from the First Phase 1 Clinical Study of the B-Cell Maturation Antigen (BCMA) Nex T Chimeric Antigen Receptor (CAR) T Cell Therapy CC-98633/BMS-986354 in Patients (pts) with Relapsed/Refractory Multiple Myeloma (RRMM)

Luciano J. Costa, Shaji K Kumar, Shebli Atrash, Michaela Liedtke, Gurbakhash Kaur, Benjamin A. Derman, P. Leif Bergsagel, Sham Mailankody, Philip L. McCarthy, Josiana Limones, Yanping Chen, Sharmila Das, Jerill Thorpe, Jonathan Cacciatore, Garnet Navarro, Ashley K Koegel, Michael R. Burgess, Kristen Hege, Shambavi Richard

Blood (2022) 140 (Supplement 1): 1360–1362.

https://doi.org/10.1182/blood-2022-160038

Published: 2022

Journal Articles

Health-Related Quality of Life for Frail Transplant-Ineligible Patients with Newly Diagnosed Multiple Myeloma Treated with Daratumumab, Lenalidomide and Dexamethasone: Subgroup Analysis of MAIA Trial

Blood (2022) 140 (Supplement 1): 1142–1145.

https://doi.org/10.1182/blood-2022-165524

Published: 2022

Journal Articles

Daratumumab Plus Lenalidomide and Dexamethasone (D-Rd) Versus Lenalidomide and Dexamethasone (Rd) in Transplant-Ineligible Patients (Pts) with Newly Diagnosed Multiple Myeloma (NDMM): Clinical Assessment of Key Subgroups of the Phase 3 Maia Study

Blood (2022) 140 (Supplement 1): 7297–7300.

https://doi.org/10.1182/blood-2022-163494

Published: 2022

Journal Articles

A Simple Risk-Scoring Model for Estimating the Prognostic Impact of 1q Gain in Patients with Newly-Diagnosed Multiple Myeloma

Fengyan Jin, Peiyu Yang, Haimin Chen, Xinyue Liang, Weiling Xu, Shanshan Yu, Wenyang Huang, Xingchen Yi, Qiang Guo, Mengru Tian, Tingting Yue, Mengyao Li, Yingjie Zhang, Mengxue Zhang, Yurong Yan, Zhongli Hu, Shaji K Kumar, Fan Zhou, Yun Dai

Blood (2022) 140 (Supplement 1): 4360–4361.

https://doi.org/10.1182/blood-2022-168602

Published: 2022

Journal Articles

Impact of Venetoclax Exposure on Clinical Efficacy and Safety in Biomarker-Selected Patients with Relapsed or Refractory Multiple Myeloma: Implication for Dose Selection

Mohamed A Badawi, Sheryl Coppola, Doerthe Eckert, Sathej Gopalakrishnan, Eva Doelger, Edyta Dobkowska, Shaji K Kumar, Weize Huang, Rajeev Menon, Ahmed Hamed Salem

Blood (2022) 140 (Supplement 1): 4281–4282.

https://doi.org/10.1182/blood-2022-166584

Published: 2022

Journal Articles

Prognostic Value of Month 1 Bone Marrow and PET MRD Status in CAR-T Therapy for Myeloma

Radhika Bansal, Sikander Ailawadhi, Jeremy T. Larsen, Morie A Gertz, Matthew A. Hathcock, David Dingli, Prashant Kapoor, Taxiarchis Kourelis, Suzanne R. Hayman, Rahma M Warsame, Moritz Binder, Ricardo D Parrondo, Rafael Fonseca, P. Leif Bergsagel, Shaji K Kumar, Yi Lin

Blood (2022) 140 (Supplement 1): 1862–1864.

https://doi.org/10.1182/blood-2022-166662

Published: 2022

Journal Articles

TET2 Down-Regulation Confers Bortezomib Resistance in Multiple Myeloma

Yun Dai, Xiaobo Liu, Ting Yang, Shaji K Kumar, Fengyan Jin

Blood (2022) 140 (Supplement 1): 4185–4186.

https://doi.org/10.1182/blood-2022-168239

Published: 2022

Journal Articles

Outpatient Practice Pattern for Recently Approved CAR-T in Patients with Lymphoma and Multiple Myeloma

Blood (2022) 140 (Supplement 1): 2399–2401.

https://doi.org/10.1182/blood-2022-167187

Published: 2022

Journal Articles

Waldenstrom Macroglobulinemia and the Clinical Implications of Acquired Von Willebrand Syndrome

Karan Chohan, Saurabh Zanwar, Ronald Go, Jonas Paludo, Carrie A. Thompson, Asher Chanan-Khan, Sikander Ailawadhi, Thomas M. Habermann, Thomas E. Witzig, Morie A Gertz, Stephen M. Ansell, Shaji K Kumar, Rajiv K. Pruthi, William L. Nichols, Prashant Kapoor, Meera Sridharan, Jithma P. Abeykoon

Blood (2022) 140 (Supplement 1): 9363–9365.

https://doi.org/10.1182/blood-2022-168232

Published: 2022

Journal Articles

Outcomes of Allogeneic Stem Cell Transplant for Multiple Myeloma

Walker M Schmidt, Francis K. Buadi, Suzanne R. Hayman, Shaji K Kumar, Angela Dispenzieri, David Dingli, Joselle Cook, Martha Q. Lacy, Prashant Kapoor, Nelson Leung, Eli Muchtar, Rahma M Warsame, Taxiarchis Kourelis, Moritz Binder, Wilson I. Gonsalves, Morie A. Gertz

Blood (2022) 140 (Supplement 1): 7182–7184.

https://doi.org/10.1182/blood-2022-156078

Published: 2022

Journal Articles

A Single Next Generation Sequencing Assay for Detection of Driver Mutations, Translocations and Copy Number Alterations in Patients with Multiple Myeloma

Cecilia Bonolo De Campos, James B Smadbeck, Mariano Arribas, Neeraj Sharma, Gregory J Ahmann, Shaji K Kumar, A. Keith Stewart, Rafael Fonseca, P. Leif Bergsagel, Yan Asmann, Linda B. Baughn, Esteban Braggio

Blood (2022) 140 (Supplement 1): 7180–7181.

https://doi.org/10.1182/blood-2022-170749

Published: 2022

Journal Articles

Variation in the Immune Tumor Microenvironment in Relation to Self-Reported Race in Individuals with Multiple Myeloma

Neeraj Sharma, Hongwei Tang, Huihuang Yan, Shulan Tian, Suganti Shivaram, Taxiarchis Kourelis, Shaji K Kumar, Linda B. Baughn

Blood (2022) 140 (Supplement 1): 4209–4210.

https://doi.org/10.1182/blood-2022-166744

Published: 2022

Journal Articles

Artificial Intelligence-Enhanced Models to Predict Light Chain Amyloidosis from Patients with Monoclonal Gammopathy of Undetermined Significance and Smoldering Multiple Myeloma

Eli Muchtar, Surendra Dasari, Martha Grogan, Morie A. Gertz, Martha Q. Lacy, Francis K. Buadi, David Dingli, Taxiarchis Kourelis, Itzhak Z. Attia, Francisco Lopez-Jimenez, Dennis Murphree, Paul A. Friedman, Shaji K Kumar, Angela Dispenzieri

Blood (2022) 140 (Supplement 1): 7230–7232.

https://doi.org/10.1182/blood-2022-168119

Published: 2022

Journal Articles

Single-Cell Dissection of Primary Quadruplet- and Triplet-Resistant Multiple Myeloma

Moritz Binder, Amelia Mazzone, Jenna A. Fernandez, Wazim Mohammed Ismail, S. Vincent Rajkumar, Alexandre Gaspar Maia, Shaji K Kumar

Blood (2022) 140 (Supplement 1): 9978–9979.

https://doi.org/10.1182/blood-2022-162679

Published: 2022

Journal Articles

AI-Enabled Screening for Drug Repurposing in Monoclonal Gammopathy of Undetermined Significance

Alexander J Ryu, Shaji K Kumar, Angela Dispenzieri, Robert A. Kyle, S. Vincent Rajkumar, Thomas C Kingsley

Blood (2022) 140 (Supplement 1): 7842–7843.

https://doi.org/10.1182/blood-2022-169376

Published: 2022

Journal Articles

Validation of a Novel Rac1 Inhibitor As Potent Secdrug Against Activating Ras Mutant and Drug-Resistant Multiple Myeloma

Salsabil Ahmed, Suman Mazumder, Lisa Wiesen, Neeraj Sharma, Ujjal Kumar Mukherjee, Shaji K Kumar, Linda B. Baughn, Brian G. Van Ness, Amit Kumar Mitra

Blood (2022) 140 (Supplement 1): 4249–4250.

https://doi.org/10.1182/blood-2022-164501

Published: 2022

NARROW

Comparison of progression risk of monoclonal gammopathy of undetermined significance by method of detection

Dexamethasone dose intensity does not impact outcomes in newly diagnosed multiple myeloma: a secondary SWOG analysis

Prognostic impact of cytogenetic abnormalities by FISH in AL amyloidosis with daratumumab-based frontline therapy

Impact of cytogenetic abnormalities on the risk of disease progression in solitary bone plasmacytomas

Results from the First Phase 1 Clinical Study of the B-Cell Maturation Antigen (BCMA) Nex T Chimeric Antigen Receptor (CAR) T Cell Therapy CC-98633/BMS-986354 in Patients (pts) with Relapsed/Refractory Multiple Myeloma (RRMM)

Health-Related Quality of Life for Frail Transplant-Ineligible Patients with Newly Diagnosed Multiple Myeloma Treated with Daratumumab, Lenalidomide and Dexamethasone: Subgroup Analysis of MAIA Trial

Daratumumab Plus Lenalidomide and Dexamethasone (D-Rd) Versus Lenalidomide and Dexamethasone (Rd) in Transplant-Ineligible Patients (Pts) with Newly Diagnosed Multiple Myeloma (NDMM): Clinical Assessment of Key Subgroups of the Phase 3 Maia Study

A Simple Risk-Scoring Model for Estimating the Prognostic Impact of 1q Gain in Patients with Newly-Diagnosed Multiple Myeloma

Impact of Venetoclax Exposure on Clinical Efficacy and Safety in Biomarker-Selected Patients with Relapsed or Refractory Multiple Myeloma: Implication for Dose Selection

Prognostic Value of Month 1 Bone Marrow and PET MRD Status in CAR-T Therapy for Myeloma

TET2 Down-Regulation Confers Bortezomib Resistance in Multiple Myeloma

Outpatient Practice Pattern for Recently Approved CAR-T in Patients with Lymphoma and Multiple Myeloma

Waldenstrom Macroglobulinemia and the Clinical Implications of Acquired Von Willebrand Syndrome

Outcomes of Allogeneic Stem Cell Transplant for Multiple Myeloma

A Single Next Generation Sequencing Assay for Detection of Driver Mutations, Translocations and Copy Number Alterations in Patients with Multiple Myeloma

Variation in the Immune Tumor Microenvironment in Relation to Self-Reported Race in Individuals with Multiple Myeloma

Artificial Intelligence-Enhanced Models to Predict Light Chain Amyloidosis from Patients with Monoclonal Gammopathy of Undetermined Significance and Smoldering Multiple Myeloma

Single-Cell Dissection of Primary Quadruplet- and Triplet-Resistant Multiple Myeloma

AI-Enabled Screening for Drug Repurposing in Monoclonal Gammopathy of Undetermined Significance

Validation of a Novel Rac1 Inhibitor As Potent Secdrug Against Activating Ras Mutant and Drug-Resistant Multiple Myeloma

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only